CVS Health Corp vs Thomson Reuters Corp — how do they compare? CVS Health Corp trades at $93.54 (market cap $119.58B), while Thomson Reuters Corp trades at $104.52 (market cap $45.38B). The key difference: CVS Health Corp is far larger — about 2.6× Thomson Reuters Corp's market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| CVS | TRI | |
|---|---|---|
Market Cap | $119.58B | $45.38B |
Sector | Health | Industrials |
52-Week High | $110.60 | $178.77 |
52-Week Low | $65.51 | $76.55 |
Enterprise Value | $181.93B | $48.00B |
Dividend Yield | 2.84% | 2.5% |
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →